Suzanne A. Nasser

1.4k total citations · 1 hit paper
28 papers, 1.0k citations indexed

About

Suzanne A. Nasser is a scholar working on Physiology, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Suzanne A. Nasser has authored 28 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Physiology, 10 papers in Molecular Biology and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in Suzanne A. Nasser's work include Nitric Oxide and Endothelin Effects (5 papers), Adipokines, Inflammation, and Metabolic Diseases (3 papers) and Neuropeptides and Animal Physiology (3 papers). Suzanne A. Nasser is often cited by papers focused on Nitric Oxide and Endothelin Effects (5 papers), Adipokines, Inflammation, and Metabolic Diseases (3 papers) and Neuropeptides and Animal Physiology (3 papers). Suzanne A. Nasser collaborates with scholars based in Lebanon, Qatar and Egypt. Suzanne A. Nasser's co-authors include Ali H. Eid, Firas Kobeissy, Nadine Wehbe, Ahmed F. El‐Yazbi, Elham A. Afify, Rabah Iratni, Hasan Slika, Elias Baydoun, Gianfranco Pintus and Abdullah Shaito and has published in prestigious journals such as Pharmacological Reviews, International Journal of Molecular Sciences and Biochemical Pharmacology.

In The Last Decade

Suzanne A. Nasser

27 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Therapeutic potential of flavonoids in cancer: ROS-mediated mechanisms

2022 301 citations Hasan Slika, Nadine Wehbe et al. Biomedicine & Pharmacotherapy profile →

Peers

Countries citing papers authored by Suzanne A. Nasser

Since Specialization

Citations

This map shows the geographic impact of Suzanne A. Nasser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne A. Nasser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne A. Nasser more than expected).

Fields of papers citing papers by Suzanne A. Nasser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne A. Nasser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne A. Nasser. The network helps show where Suzanne A. Nasser may publish in the future.

Co-authorship network of co-authors of Suzanne A. Nasser

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne A. Nasser. A scholar is included among the top collaborators of Suzanne A. Nasser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne A. Nasser. Suzanne A. Nasser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacological interventions targeting β-adrenoceptors in colorectal cancer: an evolving paradigm 2025 ·Inflammopharmacology ·(unknown), (unknown), (unknown), Suzanne A. Nasser, Gianfranco Pintus, Ali H. Eid	0
2	Flavonoids, gut microbiota and cardiovascular disease: Dynamics and interplay 2024 ·Pharmacological Research ·(unknown), Hasan Slika, Suzanne A. Nasser, Gianfranco Pintus, (unknown), Amirhossein Sahebkar, Ali H. Eid	16
3	C‐peptide in diabetes: A player in a dual hormone disorder? 2024 ·Journal of Cellular Physiology ·Ali Dakroub, (unknown), (unknown), Suzanne A. Nasser, Ahmed F. El‐Yazbi, Amirhossein Sahebkar, Assaad A. Eid, Rabah Iratni, Ali H. Eid	8
4	Adrenoceptor Desensitization: Current Understanding of Mechanisms 2024 ·Pharmacological Reviews ·Dina Maaliki, (unknown), Suzanne A. Nasser, Amirhossein Sahebkar, Ali H. Eid	6
5	Inflammation and hypertension: Underlying mechanisms and emerging understandings 2023 ·Journal of Cellular Physiology ·(unknown), (unknown), (unknown), Suzanne A. Nasser, Amirhossein Sahebkar, Firas Kobeissy, Ammar Boudaka, Ali H. Eid	40
6	Therapeutic potential of flavonoids in cancer: ROS-mediated mechanisms breakdown → 2022 ·Biomedicine & Pharmacotherapy ·Hasan Slika, (unknown), Nadine Wehbe, Suzanne A. Nasser, Rabah Iratni, Gheyath K. Nasrallah, Abdullah Shaito, Tarek H. Ghaddar, Firas Kobeissy, Ali H. Eid	301
7	Origanum syriacum L. Attenuates the Malignant Phenotype of MDA-MB231 Breast Cancer Cells 2022 ·Frontiers in Oncology ·Amal Al-Kahlout, Manal Fardoun, Joelle Mesmar, (unknown), Adnan Badran, Suzanne A. Nasser, (unknown), Firas Kobeissy, Abdullah Shaito, Rabah Iratni, (unknown), Elias Baydoun, Ali H. Eid	11
8	Mechanisms underlying the effects of caloric restriction on hypertension 2022 ·Biochemical Pharmacology ·(unknown), Gracia Fahed, (unknown), Shona Pedersen, Ahmed F. El‐Yazbi, Suzanne A. Nasser, Alessandra Bitto, Alexander N. Orekhov, Ali H. Eid	20
9	Inflammatory Basis of Atherosclerosis: Modulation by Sex Hormones 2021 ·Current Pharmaceutical Design ·Suzanne A. Nasser, Elham A. Afify, Firas Kobeissy, Bassam Hamam, Ali H. Eid, Mahmoud M. El‐Mas	19
10	Inflammatory Basis of Atherosclerosis: Modulation by Sex Hormones 2021 ·Current Pharmaceutical Design ·Suzanne A. Nasser	1
11	Estrogen and Bisphenol A in Hypertension 2020 ·Current Hypertension Reports ·Zena Wehbe, Suzanne A. Nasser, Ahmed F. El‐Yazbi, (unknown), Ali H. Eid	47
12	Estrogen increases expression of vascular alpha 2C adrenoceptor through the cAMP/Epac/JNK/AP-1 pathway and potentiates cold-induced vasoconstriction 2020 ·Vascular Pharmacology ·Manal Fardoun, Khodr Issa, Dina Maaliki, Suzanne A. Nasser, Elias Baydoun, Ali H. Eid	21
13	Visfatin: A Possible Role in Cardiovasculo-Metabolic Disorders 2020 ·Cells ·Ali Dakroub, Suzanne A. Nasser, Nour K. Younis, (unknown), Yusra Al-Dhaheri, Gianfranco Pintus, Assaad A. Eid, Ahmed F. El‐Yazbi, Ali H. Eid	80
14	The Role of Epac in Cancer Progression 2020 ·International Journal of Molecular Sciences ·Nadine Wehbe, Hasan Slika, Joelle Mesmar, Suzanne A. Nasser, Gianfranco Pintus, (unknown), Adnan Badran, Firas Kobeissy, Ali H. Eid, Elias Baydoun	28
15	Sex differences in pain and opioid mediated antinociception: Modulatory role of gonadal hormones 2019 ·Life Sciences ·Suzanne A. Nasser, Elham A. Afify	65
16	MicroRNAs in Cardiac Hypertrophy 2019 ·International Journal of Molecular Sciences ·Nadine Wehbe, Suzanne A. Nasser, Gianfranco Pintus, Adnan Badran, Ali H. Eid, Elias Baydoun	78
17	Facilitation by the renin-angiotensin system of cyclosporine-evoked hypertension in rats: Role of arterial baroreflexes and vasoreactivity 2016 ·Life Sciences ·Suzanne A. Nasser, Ramzi Sabra, Ahmed El‐Mallah, Mahmoud M. Mohy El‐Din, (unknown), Mahmoud M. El‐Mas	4
18	Blockade of endothelin ETA, but not thromboxane, receptors offsets the cyclosporine-evoked hypertension and interrelated baroreflex and vascular dysfunctions 2014 ·European Journal of Pharmacology ·Suzanne A. Nasser, Ahmed El‐Mallah, Ramzi Sabra, (unknown), Mahmoud M. Mohy El‐Din, Mahmoud M. El‐Mas	24
19	Endothelin ETA receptor antagonism in cardiovascular disease 2014 ·European Journal of Pharmacology ·Suzanne A. Nasser, Mahmoud M. El‐Mas	33
20	The involvement ofK_ATPchannels in morphine‐induced antinociception and hepatic oxidative stress in acute and inflammatory pain in rats 2012 ·Fundamental and Clinical Pharmacology ·Elham A. Afify, (unknown), Amal G. Omar, Suzanne A. Nasser	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact